UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(Dd) of ~~The~~the Securities Exchange Act of 1934

Date of ~~Report~~report (~~Date~~date of earliest event reported): ~~September~~December 1123, 2020

~~Lord~~LORD ~~Global~~GLOBAL ~~Corporation~~CORPORATION

(Exact ~~name~~Name of ~~Company~~Registrant as ~~specified~~Specified in its ~~charter~~Charter)

Nevada		001-36877		45-3942184
(State or other jurisdiction of Incorporation)		(Commission File Number		(IRS Employer identification Number

Commission File No.: 001-36877

Lord Global Corporation

Nevada		45-3942184
(State of Incorporation)		(I.R.S. Employer Identification No.)

318 N Carson Street, Suite 208, Carson Sity, NV		89701
(Address of Registrant’s Principal Executive Offices)		(ZIP Code)

318 N Carson St. Suite 208

Carson City, NV 89701

(Address of principal executive offices)

Registrant’s Telephone Number, including area code: (816) 304-2686

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the ~~Company under~~registrant under any of the following provisions (see General Instruction A.2. below):

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

~~Indicate~~Item by5.02 ~~check~~Departure ~~mark whether the registrant is an emerging growth company as defined in Rule 405~~ of ~~the~~Directors ~~Securities~~or ~~Act~~Certain ofOfficers; ~~1933~~Election ~~(§230.405~~ of ~~this~~Directors; ~~chapter)~~Appointment ~~or Rule 12b-2~~ of ~~the~~Certain ~~Securities~~Officers; ~~Exchange~~Compensatory ~~Act~~ Arrangements of ~~1934~~Certain ~~(§240~~Officers.~~12b-2 of this chapter).~~

~~Emerging~~On ~~growth~~December ~~company~~23, ~~[ ]~~2020, Lord Global Corporation, OTC: LRDG (“Lord Global” or the “Registrant”) received the resignation of Ms. Alexandra Aizenshtadt as Chairperson of the Registrant Board of Directors. Ms. Aizenshtadt stated in her letter of resignation, a copy of which is attached as Exhibit 17.1 hereto, that she had no disagreements with the operations, policies or practices of the Registrant The reason for her resignation was based upon the fact that Ms. Aizenshtadt no longer resides in the United States and, as a result, is unable to devote the time required to service as Chairperson of the Company’s Board of Directors.

IfItem an9.01 ~~emerging~~Financial ~~growth~~Statements ~~company,~~and indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]Exhibits

~~ITEM~~(b) The following documents are filed as exhibits to this current report on Form 8-K or incorporated by reference herein.01 ~~OTHER~~Any ~~EVENTS~~document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.

On September 11, 2020, the Company issued a press release announcing that pursuant to the agreement between 27Health Inc., the Company’s wholly owned subsidiary, and KeyOptions (https://www.keyoptions.com/), it will share in the revenues generated by the exclusive license granted to KeyOptions to market Virolens®, a 20-second COVID-19 testing product, outside of North America and Europe, in the following territories: Latin and South America, Southeast Asia, Australia, New Zealand and other Oceania countries.

Exhibit No.		Description
17.1		Letter of Resignation of Ms. Aizenshtadt dated December 23, 2020, filed herewith.

27Health Inc. entered into an administrative and financing agreement with KeyOptions, the terms of which call for 27Health Inc. to receive a significant amount of KeyOption’s revenues from Virolens and a portion of the amount of the operating margin, which is significant, in consideration for the Company issuing to KeyOptions shares of a newly authorized series of a convertible preferred stock which grants KeyOptions the right to convert the new preferred stock into 1.5 million shares of common stock after six months, with an additional 1.5 million shares that would vest after one year, based upon certain milestones. The right to convert the new series of preferred stock is expressly subject to beneficial ownership limitations which provides that at no time may KeyOptions exercise its conversion rights if, as a result of such conversion, KeyOptions would own in excess of 4.99% of the Company’s common stock.SIGNATURES

APursuant ~~copy~~to the requirements of the ~~press~~Securities ~~release~~Exchange isAct ~~attached~~of ~~hereto~~1934, asthe ~~Exhibit~~Company ~~99.1~~has ~~and~~duly ~~incorporated~~caused ~~herein~~this report to be signed on its behalf by ~~reference~~the undersigned hereunto duly authorized.

~~ITEM 9.01—FINANCIAL~~Lord ~~STATEMENTS~~Global ~~AND~~Corporation ~~EXHIBITS~~By: /s/ Joseph Frontiere Name: Joseph Frontiere Title: Chief Executive Officer

~~The~~Date: ~~following~~April is21, ~~filed as an exhibit to this report:~~2021

Exhibit Number		Title of Document
99.1		Press Release issued by the Company dated September 11, 2020, filed herewith.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 11, 2020
	LORD GLOBAL CORPORATION
	By:	/s/ Joseph Frontiere
	Name:	Joseph Frontiere
	Title:	Chief Executive Officer

Filing Compare · Lord Global Corp